Orion Pharma Limited announcements
187 Dhaka Stock Exchange announcements for Orion Pharma Limited (ORIONPHARM) since 2013: results, dividends, board meetings, AGMs, record dates and other price-sensitive information. Showing 2013 (27).
- (Q3): As per un-audited quarterly accounts for the 3rd quarter ended on 30th September 2013 (July'13 to Sep'13), the Com
(Q3): As per un-audited quarterly accounts for the 3rd quarter ended on 30th September 2013 (July'13 to Sep'13), the Company has reported consolidated net profit after tax (excluding non-controlling interests) of Tk. 229.86 million with consolidated EPS of Tk. 0.98 as against Tk. 368.08 million and Tk. 1.90 (restated) respectively for the same period of the previous year. Whereas consolidated net profit after tax (excluding non-controlling interests) was Tk. 772.17 million with consolidated EPS of Tk. 3.30 for the period of nine months (Jan'13 to Sep'13) ended on 30.09.2013 as against Tk. 774.84 million and Tk. 3.99 (restated) respectively for the same period of the previous year.
- Credit Rating
Credit Rating Agency of Bangladesh Limited (CRAB) has announced the entity rating (surveillance) of the Company as "A1" based on audited financial statements up to December 31, 2012, Bank liability position as of June 30, 2013 and other relevant quantitative as well as qualitative information up to the date of rating declaration.
- Credit Rating Agency of Bangladesh Limited (CRAB) has announced the entity rating (surveillance) of the Company as "A1"
Credit Rating Agency of Bangladesh Limited (CRAB) has announced the entity rating (surveillance) of the Company as "A1" based on audited financial statements up to December 31, 2012, Bank liability position as of June 30, 2013 and other relevant quantitative as well as qualitative information up to the date of rating declaration.
- (H/Y): As per un-audited half yearly accounts as on 30.06.2013 (Jan'13 to June'13), the Company has reported consolidate
(H/Y): As per un-audited half yearly accounts as on 30.06.2013 (Jan'13 to June'13), the Company has reported consolidated net profit after tax (excluding non-controlling interests) of Tk. 542.31 million with consolidated EPS of Tk. 2.32 as against Tk. 558.20 million and Tk. 2.88 (restated) respectively for the same period of the previous year. Whereas consolidated net profit after tax (excluding non-controlling interests) was Tk. 248.14 million with consolidated EPS of Tk. 1.06 for the period of 3 months (Apr'13 to June'13) ended on 30.06.2013 as against Tk. 315.65 million and Tk. 1.63 (restated) respectively for the same period of the previous year.
- Category Change
The Company will be placed in "A" category from existing "N" category with effect from July 25, 2013 as the Company reported disbursement of cash dividend @ 20% and stock dividend @ 20% for the year ended on December 31, 2012.
- The Company will be placed in "A" category from existing "N" category with effect from July 25, 2013 as the Company repo
The Company will be placed in "A" category from existing "N" category with effect from July 25, 2013 as the Company reported disbursement of cash dividend @ 20% and stock dividend @ 20% for the year ended on December 31, 2012.
- Normal trading of the shares of the Company will resume on 16.06.2013 after record date for EGM.
Normal trading of the shares of the Company will resume on 16.06.2013 after record date for EGM.
- Trading of the shares of the Company will remain suspended on record date i.e., 13.06.2013 for EGM.
Trading of the shares of the Company will remain suspended on record date i.e., 13.06.2013 for EGM.
- Trading of the shares of the Company will be allowed only in the Spot Market and Block/Odd lot transactions will also be
Trading of the shares of the Company will be allowed only in the Spot Market and Block/Odd lot transactions will also be settled as per Spot settlement cycle from 10.06.2013 to 12.06.2013. Trading of the shares of the Company will remain suspended on record date i.e., 13.06.2013 for EGM.
- (continuation of news of ORIONPHARM): (b) to change the proposed Pharma Park (Expansion unit) from Valuka, Mymensing to
(continuation of news of ORIONPHARM): (b) to change the proposed Pharma Park (Expansion unit) from Valuka, Mymensing to Siddirganj, Narayanganj. Date of EGM: 24.06.2013, Time of EGM: 11:00 AM, Venue: Sumilpara, Siddirganj, Narayanganj (South adjacent of Adamjee EPZ). Record date for EGM: 13.06.2013. (end)
The first part of this announcement is missing from the archive. - The Company has informed that the Board of Directors of the Company has decided the following: (a) to include a further
The Company has informed that the Board of Directors of the Company has decided the following: (a) to include a further provisions as object sub clause to the following extent; "to mortgage the property and asset of the company (including shares) as security, or to sign any guarantee/corporate guarantee under any terms and conditions for the purpose of securing loans (s) and or any credit facilities to be given by any financer or a group of financers to any other associate company or companies, sister concern and /or any other company or person and also to give guarantee or corporate guarantee or stands as guarantor or surety securing liability of such associate company sister concern or companies or any other company or person" (cont.)
- (Q1): As per un-audited quarterly accounts for the 1st quarter ended on 31st March 2013 (Jan'13 to March'13), the Compan
(Q1): As per un-audited quarterly accounts for the 1st quarter ended on 31st March 2013 (Jan'13 to March'13), the Company has reported consolidated net profit after tax (excluding non-controlling interest) of Tk. 294.17 million with consolidated basic EPS of Tk. 1.51 as against Tk. 242.56 million and Tk. 1.56 respectively for the same period of the previous year. However, considering proposed bonus share @ 20% for the year 2012, consolidated restated basic EPS will be Tk. 1.26 as on 31.03.2013 and Tk. 1.25 as on 31.03.2012.
- Normal trading of the shares of the Company will resume on 27.05.2013 after record date.
Normal trading of the shares of the Company will resume on 27.05.2013 after record date.
- Trading of the shares of the Company will remain suspended on record date i.e., 26.05.2013.
Trading of the shares of the Company will remain suspended on record date i.e., 26.05.2013.
- Trading of the shares of the Company will be allowed only in the Spot Market and Block/Odd lot transactions will also be
Trading of the shares of the Company will be allowed only in the Spot Market and Block/Odd lot transactions will also be settled as per Spot settlement cycle with cum benefit from 20.05.2013 to 22.05.2013. Trading of the shares of the Company will remain suspended on record date i.e., 26.05.2013.
- There will be no price limit on the trading of the shares of the Company today (15.05.2013) following its corporate decl
There will be no price limit on the trading of the shares of the Company today (15.05.2013) following its corporate declaration.
- The Board of Directors has recommended cash dividend @ 20% (i.e. Tk. 2.00 per share of Tk. 10.00 each) and stock dividen
The Board of Directors has recommended cash dividend @ 20% (i.e. Tk. 2.00 per share of Tk. 10.00 each) and stock dividend @ 20% for the year ended on December 31, 2012. Date of AGM: 24.06.2013, Time: 10:30 AM, Venue: Orion Pharma Plant, Sumilpara, Siddhirgonj, Narayangonj (South Adjacent of Adamjee EPZ, Siddhirgonj, Narayangonj). Record date: 26.05.2013. The Company has also reported EPS of Tk. 6.02, NAV per share of Tk. 82.42 and NOCFPS of Tk. 18.97 for the year ended on December 31, 2012.
- As per Regulation 30 of DSE Listing Regulations, the Company has informed that a meeting of the Board of Directors will
As per Regulation 30 of DSE Listing Regulations, the Company has informed that a meeting of the Board of Directors will be held on May 14, 2013 at 4:00 PM to consider, among others, audited financial statements of the Company for the year ended on December 31, 2012.
- The Company has informed about the commencement of construction work of Veterinary unit dated 23rd March, 2013. Total co
The Company has informed about the commencement of construction work of Veterinary unit dated 23rd March, 2013. Total cost of the plant and machineries including civil construction will be BDT 50 Cr. (approximately). The proposed unit will be setting up through state of art machineries that will facilitate to produce the varieties of products comprises of Injection, Liquid, Tablets and Powder of sachet which will enhance the existing revenue by 20% (approximately). The proposed facility will commence their commercial operation within a time frame of 6-8 months from 23.03.2013.
- (Continuation of news of ORIONPHARM-Q3)
Whereas for the period of 9 months (Jan'12 to Sept'12) ended on 30.09.12 consolidated profit after tax was Tk. 774.84 million and consolidated basic EPS was Tk. 5.00 as against consolidated profit after tax of Tk. 575.96 million and consolidated basic EPS of Tk. 3.71 for the same period of the previous year. It is to be noted that the said consolidated EPS has been calculated based on weighted average Pre-IPO paid-up number of shares i.e. 155,000,000 shares of the Company for both 2012 & 2011. However, considering Post-IPO 195,000,000 number of shares, Company's consolidated basic EPS would be Tk. 3.97 for 9 months ended on 30.09.12 (Jan'12 to Sept'12) and consolidated NAV would be Tk. 75.12 as on 30 September 2012.
- (Repeat): (Q3): The Company has reported its consolidated profit after tax Tk. 368.08 million and consolidated basic EPS
(Repeat): (Q3): The Company has reported its consolidated profit after tax Tk. 368.08 million and consolidated basic EPS Tk. 2.37 for the 3 (three) months ended on 30 September 2012 (July 2012-September 2012) as against consolidated profit after tax of Tk. 181.75 million and consolidated basic EPS of Tk. 1.17 for the same period of the previous year. It is to be noted that consolidated basic EPS has been calculated based on weighted average Pre-IPO paid-up number of shares i.e. 155,000,000 shares of the Company for both 2012 & 2011. However, considering Post-IPO 195,000,000 number of shares the Company's consolidated basic EPS for the 3 (three) months ended on 30 September 2012 would be Tk. 1.89. (cont.)
- (Continuation of news of ORIONPHARM-Q3): Whereas for the period of 9 months (Jan'12 to Sept'12) ended on 30.09.12 consol
(Continuation of news of ORIONPHARM-Q3): Whereas for the period of 9 months (Jan'12 to Sept'12) ended on 30.09.12 consolidated profit after tax was Tk. 774.84 million and consolidated basic EPS was Tk. 5.00 as against consolidated profit after tax of Tk. 575.96 million and consolidated basic EPS of Tk. 3.71 for the same period of the previous year. It is to be noted that the said consolidated EPS has been calculated based on weighted average Pre-IPO paid-up number of shares i.e. 155,000,000 shares of the Company for both 2012 & 2011. However, considering Post-IPO 195,000,000 number of shares, Company's consolidated basic EPS would be Tk. 3.97 for 9 months ended on 30.09.12 (Jan'12 to Sept'12) and consolidated NAV would be Tk. 75.12 as on 30 September 2012. (end)
The first part of this announcement is missing from the archive. - (Repeat): Trading of the shares of Orion Pharma Ltd. will commence today (March 20, 2013) at DSE under 'N' category. DSE
(Repeat): Trading of the shares of Orion Pharma Ltd. will commence today (March 20, 2013) at DSE under 'N' category. DSE Trading Code for Orion Pharma Ltd. is "ORIONPHARM" and DSE Company Code is 18486.
- trade postponded
In accordance with the direction to "maintain status quo in respect of enlistment and transaction of the shares/security of the Orion Pharma Ltd.", passed by the Hon'ble High Court Division of the Supreme Court of Bangladesh in the Rule Nisi issued against the Writ Petition No. 2873 of 2013, the trading of the shares of Orion Pharma Ltd. due to be started tomorrow, 20 March 2013, is postponed until further instruction from the concerned Court.
- trade commence trading
In reference to earlier news of postponement of trading of Orion Pharma Ltd. (news disseminated by DSE dated 19.03.2013 in view of a certificate received from Mr. S.M Jahangir Alam, LL.B. (Hon's) LL.M., Advocate, Supreme Court of Bangladesh) DSE has received another letter from Law Valley, Barristers & Advocates, informing that "the said Writ Petition has not yet been moved, not to speak of passing any order by the Hon'ble High Court Division". The matter has been verified by DSE authority, in consultation with a learned Barrister, and it was confirmed that no order has been passed. In view of all communication received, DSE has decided to commence trading of shares of Orion Pharma Ltd. from tomorrow i.e. March 20, 2013.
- Q3 Earnings
The Company has reported it's consolidated profit after tax Tk. 368.08 million and consolidated basic EPS Tk. 2.37 for the 3 (three) months ended on 30 September 2012 (July 2012-September 2012) as against consolidated profit after tax of Tk. 181.75 million and consolidated basic EPS of Tk. 1.17 for the same period of the previous year. It is to be noted that consolidated basic EPS has been calculated based on weighted average Pre-IPO paid-up number of shares i.e. 155,000,000 shares of the Company for both 2012 & 2011. However, considering Post-IPO 195,000,000 number of shares the Company's consolidated basic EPS for the 3 (three) months ended on 30 September 2012 would be Tk. 1.89. Whereas for the period of 9 months (Jan'12 to Sept'12) ended on 30.09.12 consolidated profit after tax was Tk. 774.84 million and consolidated basic EPS was Tk. 5.00 as against consolidated profit after tax of Tk. 575.96 million and consolidated basic EPS of Tk. 3.71 for the same period of the previous year. It is to be noted that the said consolidated EPS has been calculated based on weighted average Pre-IPO paid-up number of shares i.e. 155,000,000 shares of the Company for both 2012 & 2011. However, considering Post-IPO 195,000,000 number of shares, Company's consolidated basic EPS would be Tk. 3.97 for 9 months ended on 30.09.12 (Jan'12 to Sept'12) and consolidated NAV would be Tk. 75.12 as on 30 September 2012.
- listing
Orion Pharma Ltd.: Trading of the shares of Orion Pharma Ltd. will commence at DSE from March 20, 2013 under 'N' category. DSE Trading Code for Orion Pharma Ltd. is "ORIONPHARM" and DSE Company Code is 18486.
Source: Dhaka Stock Exchange announcements. Some posts before 2014 have no title, and 2014–2020 coverage is incomplete.